European Institute of Oncology / Istituto Europeo di Oncologia (IEO)

Research / Science organisation

Milano / Mailand, Italy

Publications in cooperation with FAU scientists

Go to first page Go to previous page 1 of 2 Go to next page Go to last page
Mayer, I.A., Prat, A., Egle, D., Blau, S., Alejandro Perez Fidalgo, J., Gnant, M.,... Arteaga, C.L. (2019). A phase II randomized study of neoadjuvant letrozole plus alpelisib for hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (NeO-ORB). Clinical Cancer Research, 25(10), 2975-2987.
Denkert, C., Budczies, J., Regan, M.M., Loibl, S., Dell’Orto, P., von Minckwitz, G.,... Viale, G. (2019). Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial. Breast Cancer Research and Treatment.
Govers, T.M., Hessels, D., Vlaeminck-Guillem, V., Schmitz-Draeger, B.J., Stief, C.G., Martinez-Ballesteros, C.,... Schalken, J.A. (2019). Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling study. Prostate Cancer and Prostatic Diseases, 22(1), 101-109.
Yao, J., Garg, A., Chen, D., Capdevila, J., Engstrom, P., Pommier, R.,... Kulke, M.H. (2019). Genomic profiling of NETs: a comprehensive analysis of the RADIANT trials. Endocrine-Related Cancer, 26(4), 391-403.
Capdevila, J., Bodei, L., Davies, P., Gorbounova, V., Jensen, R.T., Knigge, U.P.,... Wiedenmann, B. (2019). Unmet medical needs in metastatic lung and digestive neuroendocrine neoplasms. Neuroendocrinology, 108(1), 18-25.
Yao, J.C., Strosberg, J., Fazio, N., Pavel, M.E., Ruszniewski, P., Bergsland, E.,... Singh, S. (2018). Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx). In ANNALS OF ONCOLOGY. Munich, DE: OXFORD: OXFORD UNIV PRESS.
Yao, J.C., Yao, J.C., Fazio, N., Li, D., Pavel, M.E., Strosberg, J.,... Singh, S. (2018). ElevatION: NET-201 A Phase II Study to Evaluate the Efficacy and Safety of PDR001 in Patients with Metastatic, Well-Differentiated NET of Pancreatic/GI/Thoracic Origin or Poorly-Differentiated GEP NEC Who Have Progressed on Prior Treatment. (pp. 218-218).
Fazio, N., Carnaghi, C., Buzzoni, R., Valle, J., Valle, J., Herbst, F.,... Yao, J.C. (2018). Relationship between Metabolic Toxicity and Efficacy of Everolimus in Patients with Neuroendocrine Tumors (NETs): A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials. (pp. 211-211).
Fasching, P., Fernandez Abad, M., Garcia-Saenz, J.A., Schneeweiss, A., Guarneri, V., Colleoni, M.,... Slamon, D. (2017). Biological and clinical effects of abemaciclib in a phase 2 neoadjuvant study for postmenopausal patients with HR+/HER2-breast cancer. (pp. 225-+).
Guarneri, V., Fasching, P., Fernandez Abad, M., Garcia-Saenz, A., Schneeweiss, A., Colleoni, M.,... Slamon, D. (2017). Biological and clinical effects of abemaciclib in a phase 2 neoadjuvant study for postmenopausal patients with HR+/HER2-breast cancer. (pp. 19-19).
Guo, Q., Burgess, S., Turman, C., Bolla, M.K., Wang, Q., Lush, M.,... Pharoah, P.D.P. (2017). Body mass index and breast cancer survival: a Mendelian randomization analysis. International Journal of Epidemiology, 46(6), 1814-1822.
Pavel, M.E., Singh, S., Strosberg, J.R., Bubuteishvili-Pacaud, L., Degtyarev, E., Neary, M.P.,... Yao, J.C. (2017). Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, 18(10), 1411-1422.
Buzzoni, R., Carnaghi, C., Strosberg, J., Fazio, N., Singh, S., Herbst, F.,... Pommier, R. (2017). Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4. Oncotargets and Therapy, 10, 5013-5030.
Jiao, X., Aravidis, C., Marikkannu, R., Rantala, J., Picelli, S., Adamovic, T.,... Lindblom, A. (2017). PHIP - a novel candidate breast cancer susceptibility locus on 6q14.1. Oncotarget, 8(61), 102769-102782.
Higgins, M., Curigliano, G., Dieras, V., Kuemmel, S., Kunz, G., Fasching, P.,... Goss, P. (2017). Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study. Breast Cancer Research and Treatment, 162(3), 479-488.
Hamdi, Y., Soucy, P., Adoue, V., Michailidou, K., Canisius, S., Lemacon, A.,... Simard, J. (2016). Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21. Oncotarget, 7(49), 80140-80163.
Ghoussaini, M., French, J.D., Michailidou, K., Nord, S., Beesley, J., Canisus, S.,... Edwards, S.L. (2016). Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation. American Journal of Human Genetics, 99(4), 903-911.
Horne, H.N., Chung, C.C., Zhang, H., Yu, K., Prokunina-Olsson, L., Michailidou, K.,... Figueroa, J.D. (2016). Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus. PLoS ONE, 11(8).
Guo, Y., Andersen, S.W., Shu, X.-O., Michailidou, K., Bolla, M.K., Wang, Q.,... Zheng, W. (2016). Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent. Plos Medicine, 13(8).
Liu, J., Loncar, I., Collee, J.M., Bolla, M.K., Dennis, J., Michailidou, K.,... Hollestelle, A. (2016). rs2735383, located at a microRNA binding site in the 3'UTR of NBS1, is not associated with breast cancer risk. Scientific Reports, 6.

Last updated on 2016-22-06 at 08:39